BSX241213C93000
- 0.01
- -0.07-87.50%
Boston Scientific Newsroom
Boston Scientific Is Maintained at Buy by TD Cowen
Boston Scientific Analyst Ratings
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $110
TD Cowen Adjusts Price Target on Boston Scientific to $110 From $100, Maintains Buy Rating
Citigroup Adjusts Boston Scientific Price Target to $107 From $98, Maintains Buy Rating
Boston Scientific Is Maintained at Overweight by Wells Fargo
Boston Scientific Analyst Ratings
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $100
Citi Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $107
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $98
Boston Scientific's Promising Clinical Trials and Innovative Approaches Justify Buy Rating
Boston Scientific Analyst Ratings
Canaccord Genuity Adjusts Price Target on Boston Scientific to $101 From $98, Keeps Buy Rating
CCORF Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $101
Piper Sandler Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $95
Piper Sandler Sticks to Their Buy Rating for Boston Scientific (BSX)
Needham Maintains Boston Scientific(BSX.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ventyx Biosciences (VTYX)
Boston Scientific Analyst Ratings
Piper Sandler Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $95